RNAC
Cartesian Therapeutics·NASDAQ
--
--(--)
--
--(--)
4.55 / 10
Netural
Fund flow evaluation: 7.77/10 reflecting robust fund flow characteristics. Constructive Medium and Large trends face headwinds from adverse overall, block, Small, and Extra-large developments, indicating positive money flow direction. Research analyst consensus shows overwhelmingly bullish analyst consensus, demonstrating strong conviction. Current ratings: Strong Buy(33.3%), Buy(66.7%) across 3 coverage providers, supported by 1.34 historical weighted rating.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
33%
Buy
67%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-03-09
InstitutionNeedham
Times predicted4
Historical Win Rate25.0%
What is the analyst consensus for RNAC?
- RNAC holds a Bearish analyst rating, with 67% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 4.55/10 (Netural).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
